Public-registry trials using KH607 tablets that Eichor's radar has found — 2 trials. All data below is from public sources; Eichor is not affiliated with any sponsor.
| Trial | Sponsor | Condition | Phase | Sites |
| A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Major Depressive Disorder (MDD) | PHASE3 | 0 |
| Compare the Efficacy and Safety of KH607 Tablets Versus Vortioxetine Hydrobromide Tablets in Adult Patients With Major Depressive Disorder | Chengdu Kanghong Pharmaceutical Group Co., Ltd. | Major Depressive Disorder (MDD) | PHASE3 | 0 |
Eichor generates a preliminary site-risk snapshot — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
